Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma (OTCQB: BETRF) appointed Doug Drysdale, formerly CEO of Cybin, as Executive Chairman and Director. Drysdale previously led Cybin from molecule inception to Phase 3 trials in three years and is recognized for advocating innovation in mental healthcare.
BetterLife granted him stock options for 3,500,000 shares at an exercise price of $0.065, vesting monthly over 24 months with a 10-year term.
BetterLife Pharma (OTCQB: BETRF) will participate in the YAFO Capital Access Asia 2025 Partnering Forum in San Francisco during JPM Week, with the YAFO event on January 11, 2026.
CEO Dr. Ahmad Doroudian will attend additional meetings: H7 Life Science Investment Forum & China Night Reception on January 12, 2026, WuXi Global Forum on January 13, 2026, and DARPA & Ferocity Capital Biodefence Summit on January 13, 2026. He is available for one-on-one meetings with investors and partners; scheduling requests are directed to the CEO's contact.
BetterLife is developing BETR-001, a patented stereoisomer of 2-bromo-LSD described as a non-hallucinogenic neuroplastogen being studied for traumatic brain injury, PTSD, and cluster headache; a small prior study (Karst et al, Cephalgia 2010) reported reduced cluster headache frequency.
BetterLife Pharma (OTCQB: BETRF) announced an engagement agreement dated December 11, 2025 to retain Shanghai-based YAFO Capital as its exclusive advisor for seeking strategic partnerships for development of BETR-001 in the Greater China region (mainland China, Hong Kong, Taiwan and Macau).
The company said it will retain YAFO on a non-exclusive basis for territories outside Greater China. BETR-001 is described as a patented, non-hallucinogenic stereoisomer of 2-bromo-LSD being developed for traumatic brain injury, PTSD and cluster headache.
BetterLife Pharma (BETRF) presented promising scientific data for its drug candidate BETR-001, a non-hallucinogenic neuroplastogen, at the Bloom Burton Conference. The research demonstrated BETR-001's superior ability to induce neuroplasticity in rat brain cortical neurons compared to ketamine, showing significant formation of new spines and increased neuronal dendrite growth.
BETR-001 is being developed to treat various psychiatric and neurological conditions, including depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain. The company has secured USPTO patent protection for BETR-001's composition of matter and completed most IND-enabling studies. BetterLife plans to file its IND application and initiate human trials in H1 2026.
BetterLife Pharma (OTCQB: BETRF), a biotech company developing BETR-001 for psychiatric and neurological disorders, has announced significant debt settlements through share issuance. The company issued 14,999,303 common shares to settle accounts payable and amounts due totaling $1,499,930. Of this, company officers and directors settled $1.03 million in debt for 10,308,039 shares. Additionally, BetterLife raised $25,000 through the exercise of 250,000 share purchase warrants. The newly issued shares will be subject to a four-month hold period under Canadian securities laws.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed André Beaudry as Corporate Advisor. Beaudry brings over 30 years of experience in fundraising, government relations, and international program management, having secured over $140M for various initiatives including mental health across multiple countries.
As Founder of Velocity Collaboration , Beaudry is also a shareholder of BetterLife and will focus on advancing BETR-001, the company's patented non-hallucinogenic compound. The drug has completed most FDA required IND-enabling studies and aims to treat anxiety, depression, PTSD, addiction, chronic migraine, and cluster headaches by renewing neural circuits affected by chronic stress or trauma.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha brings 25 years of experience in investment banking, business development, and asset management, along with expertise in public company governance and compliance. He holds a Doctorate of Dental Surgery from the University of Western Ontario and a Bachelor of Pharmaceutical Science from UBC.
As the largest shareholder of BetterLife, Dr. Sangha expressed confidence in BETR-001, describing it as the best asset in its class for treating depression, anxiety, PTSD, and addiction. The company is focusing on developing non-hallucinogenic compounds for psychiatric and neurological disorders, with plans to advance BETR-001 to human clinical trials in the near future.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF / FRA: NPAU), a biotech company developing BETR-001 (a non-hallucinogenic LSD derivative), has announced debt conversions. The company has issued 642,329 common shares and an equal number of share purchase warrants following the conversion of convertible debentures and accrued interest totaling $64,232.88.
The share purchase warrants can be exercised on a one-for-one basis at $0.10 per warrant, with expiration dates set for September 27, 2026, and October 29, 2026.